NeuroScientific Biopharmaceuticals' Matt Liddelow sits down with Proactive to paint a picture of the company's current operations and future plans. The healthcare stock is developing novel, peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have a high unmet medical need. Ultimately, NSB's vision is to transform how the pharmaceutical industry approaches the understanding and treatment of neurodegenerative diseases such as Alzheimer’s disease.
